<DOC>
	<DOCNO>NCT00099333</DOCNO>
	<brief_summary>This study look safety substitute exenatide insulin patient type 2 diabetes currently take insulin oral antidiabetic agent ( ) .</brief_summary>
	<brief_title>Study Safety Substituting Exenatide Insulin Patients Using Insulin Oral Antidiabetic Agents</brief_title>
	<detailed_description>This exploratory , multicenter , open-label , 2-arm , parallel trial . Approximately 30 patient type 2 diabetes , currently sulfonylurea , meglitinide and/or metformin insulin therapy , randomize discontinue insulin substitute exenatide remain current diabetes therapy regimen . All patient continue current diet exercise regimen study .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Hypoglycemic Agents</mesh_term>
	<criteria>Patients treat insulin &gt; =3 month 12 year . HbA1c &lt; =10.5 % . Body mass index ( BMI ) 27 kg/m2 40 kg/m2 . Patients previously receive exenatide GLP1 analog . Patients treat great 2 week thiazolidinediones alphaglucosidase inhibitor within 3 month prior screen .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>exenatide</keyword>
	<keyword>exendin-4</keyword>
	<keyword>Amylin</keyword>
	<keyword>Eli Lilly</keyword>
	<keyword>diabetes</keyword>
</DOC>